Symbols

PGEN

Precigen·NASDAQ

--(--)

PGEN fundamentals

PGEN Q4 2025 Earnings

Precigen (PGEN) released its earnings on Mar 25, 2026: revenue was 9.66M (YoY +711.51%), beat estimates; EPS was -0.07 (YoY +5.02%), beat estimates.

Revenue / YoY

9.66M

+711.51%

EPS / YoY

-0.07

+5.02%

Report date

Mar 25, 2026

PGEN Earnings Call Summary for Q4,2025

Q1 Revenue Surges: Exceeds $18 million, up from $3.4 million in Q4 2025, driven by Papzimeos launch.
Payer Coverage: 90% of U.S. insured lives covered, with J-code streamlining access.
European Expansion: MAA under review, targeting 2026 approval.
Financial Health: $100.4 million cash on hand, on track for 2026 breakeven.

Earnings

EPS

Revenue

Revenue & Expenses

PGEN has released its 2025 Q4 earnings report, with revenue of 4.57M, reflecting a YoY change of 283.61%, and net profit of -23.50M, showing a YoY change of -19.14%. The Sankey diagram below clearly presents PGEN's revenue sources and cost distribution.

Key Indicators

Precigen (PGEN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Precigen (PGEN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Precigen (PGEN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Precigen (PGEN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown